{"analyses":[{"groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"= 0.081","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.7","value":"0.94"},{"groupId":"OG001","spread":"0.5","value":"0.88"},{"groupId":"OG002","spread":"0.7","value":"-0.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"}],"units":"Participants"}],"description":"Percentage change of Bone Mineral Density after one year of treatment from baseline.\n\nMeasured with Dual-energy X-ray absorptiometry (DXA)-scan.","dispersionType":"Standard Error","groups":[{"description":"15 subjects were treated with combined 60mg denosumab every six months, 30 mg cinacalcet daily and 50 micrograms vitamin-D3 daily.","id":"OG000","title":"Combined Treatment."},{"description":"16 subjects received 60 mg denosumab every six months, placebo and 50 micrograms vitamin-D daily.","id":"OG001","title":"Denosumab Monotherapy"},{"description":"15 subjects will receive a saline injection every six months(blinded), placebo-tablets and 50 micrograms vitamin-D daily.","id":"OG002","title":"Placebo"}],"paramType":"MEAN","populationDescription":"One participant from the combined treatment-group was not included in the analysis due to withdrawal before the final scan. One participant from the denosumab group did not provide results for this analysis as he/she experienced a wrist fracture prior to the final scan.","reportingStatus":"POSTED","timeFrame":"Baseline,one year","title":"Percentage Change in 1/3 Forearm Bone Mineral Density","type":"PRIMARY","unitOfMeasure":"% change"}